{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:03:09Z","timestamp":1788825789747,"version":"build-2803163510"},"reference-count":37,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Approximately 3\u201313% of patients with psoriasis are first affected after age 60 years. Numerous studies have investigated the use of biologic agents for the treatment of psoriasis, but the routine exclusion of elderly adults from clinical trials has limited our knowledge about their effects in this age group. Background\/Objectives: This study aimed to investigate the efficacy and safety of biologic drugs for the treatment of psoriasis in elderly patients. Methods: A single-center-based retrospective cohort study design was used. A total of 149 elderly patients with psoriasis were divided into two groups by age at initiation of biologic treatment: &lt;65 years (adult-start group) and &gt;65 years (elderly-start group). Data on patient characteristics were collected and analyzed, and drug survival was evaluated. Results: Demographics, comorbidities, and treatment turnover were similar in the adult-start and elderly-start groups. Drug survival of adalimumab as first-line treatment, and of guselkumab in any treatment sequence, was significantly better in the elderly-start group (p = 0.029 and p = 0.032, respectively). There was no between-group difference in drug safety, as reflected in hospitalizations for infection or death. Conclusions: Biologic treatments for psoriasis demonstrate both efficacy and safety in elderly patients. Some agents exhibited better drug survival when initiated after age 65 years.<\/jats:p>","DOI":"10.3390\/jcm14134779","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T06:03:13Z","timestamp":1751868193000},"page":"4779","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Systemic Biologic Treatment for Psoriasis in Elderly Patients"],"prefix":"10.3390","volume":"14","author":[{"given":"Sapir","family":"Glazer Levavi","sequence":"first","affiliation":[{"name":"Division of Dermatology, Rabin Medical Center, Beilinson Hospital, Petach Tikva 49100, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronny","family":"Maman","sequence":"additional","affiliation":[{"name":"Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv 69978, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2323-3512","authenticated-orcid":false,"given":"Shany","family":"Sherman","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Rabin Medical Center, Beilinson Hospital, Petach Tikva 49100, Israel"},{"name":"Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv 69978, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7158-2085","authenticated-orcid":false,"given":"Daniel","family":"Mimouni","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Rabin Medical Center, Beilinson Hospital, Petach Tikva 49100, Israel"},{"name":"Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv 69978, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8400-9587","authenticated-orcid":false,"given":"Lev","family":"Pavlovsky","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Rabin Medical Center, Beilinson Hospital, Petach Tikva 49100, Israel"},{"name":"Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv 69978, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2133.2012.11208.x","article-title":"Long-Term Safety of Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: Review of Current Data","volume":"167","author":"Rustin","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jdv.13854","article-title":"A Systematic Review of Worldwide Epidemiology of Psoriasis","volume":"31","author":"Michalek","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/1203475419897578","article-title":"Biologic Treatment in Elderly Patients with Psoriasis: A Systematic Review","volume":"24","author":"Sandhu","year":"2020","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40266-014-0156-6","article-title":"Managing Moderate-to-Severe Psoriasis in the Elderly","volume":"31","author":"Balato","year":"2014","journal-title":"Drugs Aging"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"adv00805","DOI":"10.2340\/actadv.v102.2412","article-title":"Safety Assessment of Conventional and Biological Systemic Therapy in Older Adults with Psoriasis, a Real-World Multicentre Cohort Study","volume":"102","author":"Bronkhorst","year":"2022","journal-title":"Acta Derm. Venereol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/archdermatol.2011.2768","article-title":"Risk of Serious Adverse Events Associated with Biologic and Nonbiologic Psoriasis Systemic Therapy: Patients Ineligible vs Eligible for Randomized Controlled Trials","volume":"148","author":"Carretero","year":"2012","journal-title":"Arch. Dermatol."},{"key":"ref_9","first-page":"1","article-title":"Drug Survival Studies in Dermatology:Principles, Purposes, and Pitfalls","volume":"135","author":"Kievit","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_10","first-page":"489","article-title":"Defining \u201celderly\u201d in Clinical Practice Guidelines for Pharmacotherapy","volume":"12","author":"Singh","year":"2014","journal-title":"Pharm. Pract."},{"key":"ref_11","unstructured":"Bolognia, J.L. (2017). Dermatology, Elsevier. [4th ed.]."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s40266-022-00961-y","article-title":"Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients-A BioCAPTURE Registry Study","volume":"39","author":"Thomas","year":"2022","journal-title":"Drugs Aging"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Osuna, C.G., Garc\u00eda, S.R., Mart\u00edn, J.C., Jim\u00e9nez, V.G., L\u00f3pez, F.V., and Santos-Juanes, J. (2021). Use of Biological Treatments in Elderly Patients with Skin Psoriasis in the Real World. Life, 11.","DOI":"10.3390\/life11121348"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ad.2014.04.004","article-title":"Drug Survival in Biologic Therapy. Do We Know What It Means? Can We Calculate It?","volume":"105","author":"Carrascosa","year":"2014","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.12688\/f1000research.122945.2","article-title":"Effectiveness, Survival and Safety of Guselkumab Attending to Basal Characteristics in Moderate-to-Severe Psoriatic Patients: A Cohort Study","volume":"11","year":"2022","journal-title":"F1000Research"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/ced.14979","article-title":"Anti-Interleukin-23 for Psoriasis in Elderly Patients: Guselkumab, Risankizumab and Tildrakizumab in Real-World Practice","volume":"47","author":"Ruggiero","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/1346-8138.12653","article-title":"Efficacy and Safety of Ustekinumab Treatment in Elderly Patients with Psoriasis","volume":"41","author":"Hayashi","year":"2014","journal-title":"J. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e1444","DOI":"10.1111\/jdv.19355","article-title":"Effectiveness and Safety of Anti-IL-23 and Anti-IL-17 Biological Therapies for Psoriasis in Elderly Patients: Real-World Experience from Two Italian Hospitals","volume":"37","author":"Fiorillo","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.cgh.2018.12.032","article-title":"Safety of Biologic Therapy in Older Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis","volume":"17","author":"Borren","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.abd.2020.08.016","article-title":"Interstitial Lung Disease Due to Anti-TNF Use in the Treatment of Psoriasis","volume":"96","author":"Oliveira","year":"2021","journal-title":"Bras. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.mayocpiqo.2018.07.006","article-title":"Interstitial Pneumonia in Psoriasis","volume":"2","author":"Kawamoto","year":"2018","journal-title":"Mayo. Clin. Proc. Innov. Qual. Outcomes"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/jdv.15139","article-title":"Elderly Psoriatic Patients under Biological Therapies: An Italian Experience","volume":"33","author":"Ricceri","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/ced.12850","article-title":"Efficacy and Safety of Ustekinumab in a Group of 22 Elderly Patients with Psoriasis over a 2-Year Period","volume":"41","author":"Megna","year":"2016","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamadermatol.2025.0144","article-title":"Systemic Therapies for Psoriatic Disease and Serious Infections in Older Adults","volume":"161","author":"Drucker","year":"2025","journal-title":"JAMA Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2425029","DOI":"10.1080\/09546634.2024.2425029","article-title":"Long-Term Effectiveness and Safety of Risankizumab in Patients with Moderate-to-Severe Psoriasis with and without Cardiometabolic Comorbidities: A Single-Center Retrospective Study","volume":"35","author":"Ibba","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40257-024-00857-0","article-title":"Managing the Patient with Psoriasis and Metabolic Comorbidities","volume":"25","author":"Bellinato","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_27","first-page":"846","article-title":"Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients with Moderate to Severe Psoriasis","volume":"14","author":"Garber","year":"2015","journal-title":"J. Drugs Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/bjd\/ljaf017","article-title":"Age and Biologic Survival in Patients with Moderate-to-Severe Psoriasis: A Cohort Study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)","volume":"192","author":"Alabas","year":"2025","journal-title":"Br. J. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1111\/jdv.20143","article-title":"Age Affects Drug Survival Rates of Interleukin (IL)-17 and IL-23 Inhibitors in Patients with Plaque Psoriasis: Results from a Retrospective, Multicentric, Multi-country, Cohort Study","volume":"38","author":"Chiricozzi","year":"2024","journal-title":"Acad. Dermatol. Venereol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamadermatol.2021.2599","article-title":"Association Between Biologics Use and Risk of Serious Infection in Patients with Psoriasis","volume":"157","author":"Penso","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"AB327","DOI":"10.1016\/j.jaad.2024.07.1303","article-title":"54665 The Efficacy and Safety of Switching From Different Biologics To Interleukin-23 Inhibitors: A Systematic Review","volume":"91","author":"Bagit","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jaad.2024.07.1473","article-title":"Interleukin 23 versus Interleukin 12\/23 Inhibitors on Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis? A Real-World Comparison from the TriNetX Global Collaborative Network","volume":"91","author":"Tsai","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_33","first-page":"111","article-title":"Prostate Cancer in Elderly Men","volume":"10","author":"Stangelberger","year":"2008","journal-title":"Rev. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jaad.2008.12.031","article-title":"Treatments for Psoriasis and the Risk of Malignancy","volume":"60","author":"Patel","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"17093","DOI":"10.1007\/s00432-023-05387-6","article-title":"Cancer Risks in Patients with Psoriasis Administered Biologics Therapy: A Nationwide Population-Based Study","volume":"149","author":"Jung","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Battista, T., Gallo, L., Martora, F., Fattore, D., Potestio, L., Cacciapuoti, S., Scalvenzi, M., and Megna, M. (2024). Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13071940"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jaad.2024.01.078","article-title":"Negative Impact of Comorbidities on All-Cause Mortality of Patients with Psoriasis Is Partially Alleviated by Biologic Treatment: A Real-World Case-Control Study","volume":"91","author":"Riaz","year":"2024","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/13\/4779\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:05:35Z","timestamp":1760033135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/13\/4779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":37,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["jcm14134779"],"URL":"https:\/\/doi.org\/10.3390\/jcm14134779","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]}}}